Saturday 17 October 2026 Export CERO’s income statement to Excel — free account

CERo Therapeutics Holdings, Inc.

In the quarter to June 2026, EPS grew 98.9% and free cash flow grew 49.7%, each against the same quarter a year earlier.

0.01 0.00 0.00%

Follow CERO

Alert me

Market cap: $140.0K
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 97.20%

Capital & Financial Ratios $m

Market Cap 0.14

Revenue —

Net Income (16.31)

Free Cash Flow (12.10)

Net Debt (0.19)

Current Ratio 0.05

Debt/Equity (0.02)

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 96.81%

Next Y EPS Growth 75.96%

Next Y revenue growth —

Next 5Y EPS Growth 81.13%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	2	3	2	1
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	2	4	3	2

	2023	2024	2025	Q'26
Payables	2	5	8	8
ST’ Debt	—	—	—	1
Other	0	0	0	23
	4	7	9	32

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(2)	—	—	—
’25	(4)	(5)	(3)	(4)	(16)
’24	(5)	(4)	(3)	(2)	(13)
’23	(1)	(2)	(1)	(1)	(6)
’22	0	0	0	0	(1)
’21	—	—	—	(1)	(1)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(2)	—	—	—
’25	(4)	(5)	(3)	(4)	(16)
’24	(5)	(4)	(3)	(2)	(13)
’23	(1)	(2)	(1)	(1)	(6)
’22	0	0	0	0	(1)
’22	—	—	—	—	(1)
’21	—	—	—	(1)	(1)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.20)	(0.70)	—	—	—
’25	(31.80)	(61.71)	(9.10)	40.02	(22.58)
’24	(326.20)	(300.00)	(180.00)	512.12	(286.64)
’23	(538.28)	(461.75)	(297.58)	(23.68k)	(24.97k)
’22	(164.48)	(48.55)	36.77	(114.30)	(290.56)
’21	—	0.00	—	(0.01)	(136.97)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	19,420.00	19,800.00	20,540.00	94.00	0.05	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	21,240.00	23,520.00	23,660.00	25,600.00	206.00
People
People	Employees	—	—	—	—	—	3	3	9	8	8
	Revenue/emp, $m	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	—	—	—	—	—	—	—
	EBT	—	—	—	—	—	0	0	(7)	(8)	(20)
	EBT margin, %	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
	Net income	—	0	—	—	—	0	(1)	(7)	(8)	(20)
	Depreciation	—	—	—	—	—	—	—	1	1	1
Per share, $
Per share, $	Revenue	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	—	—	—	(136.97)	(290.56)	(24,972.86)	(101.23)	(22.58)
	Cash flow	—	—	—	—	—	(303.09)	(474.87)	(19,300.00)	(445.38)	(3.80)
	Capex	—	—	—	—	—	0.00	0.00	0.00	0.00	0.12
	Free cash flow	—	—	—	—	—	(303.09)	(474.87)	(19,300.00)	(445.38)	(3.68)
	Book value	—	—	—	—	—	(3,334.74)	(4,782.70)	(140,192.33)	(65.33)	(1.29)
	Shares, m	—	—	—	—	—	0	0	0	0	4
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	—	(1)	(1)	(6)	(13)	(16)
	Capex	—	—	—	—	—	—	—	—	—	1
	Free cash flow	—	—	—	—	—	(1)	(1)	(6)	(13)	(16)
Balance, $m
Balance, $m	Working capital	—	—	—	—	—	1	12	(2)	(4)	(6)
	Total debt	—	—	—	—	—	—	1	2	—	—
	Net debt	—	—	—	—	—	(1)	0	(2)	(3)	(2)
	Shareholders’ equity	—	—	—	—	—	(8)	(11)	(42)	(2)	(5)
Returns, %
Returns, %	ROA	—	—	—	—	—	(0.18)	(0.60)	(30.70)	(195.70)	(1,940.02)
	ROIC	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
	ROE	—	—	—	—	—	(0.39)	7.15	27.48	47.06	1,074.49

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SEELQ Seelos Therapeutics, Inc.	$700.0K	— (loss-making)	— (loss-making)	+11.90% (above 0%: growing)	n/m	+83.54% (above 0%: growing)	100.00%	(834.84%)	Compare
ATXI Avenue Therapeutics, Inc.	$680.0K	— (loss-making)	— (loss-making)	—	n/m	−169.89% (below 0%: shrinking)	100.00%	0.00%	Compare
SCNI Scinai Immunotherapeutics Ltd. Sponsored ADR	$640.0K	0.0×	— (loss-making)	—	n/m	+51.13% (above 0%: growing)	(228.63%)	(504.50%)	Compare
BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR	$440.0K	— (loss-making)	—	−32.27% (below 0%: shrinking)	+96.36% (above 0%: growing)	−0.17% (below 0%: shrinking)	0.00%	0.00%	Compare
VINC Vincerx Pharma, Inc.	$250.0K	— (loss-making)	—	—	n/m	+42.45% (above 0%: growing)	0.00%	0.00%	Compare
CDT CDT Equity Inc.	$240.0K	— (loss-making)	—	—	n/m	+78.92% (above 0%: growing)	—	0.00%	Compare
EFTR eFFECTOR Therapeutics, Inc.	$200.0K	— (loss-making)	—	+58.08% (above 0%: growing)	n/m	+4.86% (above 0%: growing)	0.00%	0.00%	Compare
VRPX Virpax Pharmaceuticals, Inc.	$160.0K	— (loss-making)	—	—	n/m	+4.68% (above 0%: growing)	—	0.00%	Compare
CERO CERo Therapeutics Holdings, Inc.	$140.0K	0.0×	—	—	n/m	+49.65% (above 0%: growing)	—	0.00%
Median of peers	$345.0K	—	—	+11.90%	—	+23.65%	0.00%	0.00%

All 614 Biotechnology stocks →

CERo Therapeutics Holdings, Inc. (CERO) key facts

CERo Therapeutics Holdings, Inc. (CERO) is a Biotechnology company in the Healthcare sector.
As of October 16, 2026, CERO traded at $0.01, a market capitalization of $140,000.00.
Return on equity was 1,074.5% and debt-to-equity -0.02.

Source: company filings (standardised) and stockrow calculations.